Physician profile
Lori Miller
NPI 1164405338
$3,361.48
in general payments reported to CMS, 2019-2025
30 companies · $640 in 2025
The $640 reported for 2025 was more than what 96% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $318 · 2020: $331 · 2021: $473 · 2022: $530 · 2023: $404 · 2024: $665 · 2025: $640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,709.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,708.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $693.65 | 2023-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $361.86 | 2019-2024 | Dyanavel Xr, Quillichew Er |
| Corium, LLC | $228.75 | 2021-2025 | Azstarys |
| Cranial Technologies, INC | $219.57 | 2020-2025 | Doc Band |
| Collegium Pharmaceutical, INC. | $192.21 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $191.12 | 2019-2024 | |
| Alk-Abello, INC | $137.57 | 2023-2025 | Grastek, Odactra, Ragwitek |
| Kowa Pharmaceuticals America, INC. | $134.78 | 2025 | Zoryve |
| Janssen Pharmaceuticals, INC | $124.56 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $114.84 | 2021-2022 | |
| Pfizer INC. | $111.16 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $103.64 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Genentech USA, INC. | $91.19 | 2020-2021 | |
| Glaxosmithkline, LLC. | $76.70 | 2019-2025 | Bexsero |
| Astrazeneca Pharmaceuticals LP | $68.56 | 2023-2024 | Flumist Quadrivalent, Evusheld |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $63.16 | 2019-2021 | |
| Neos Therapeutics, LP | $57.06 | 2019 | |
| Adlon Therapeutics L.P. | $56.08 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $49.57 | 2024-2025 | |
| Ultragenyx Pharmaceutical INC. | $47.55 | 2020-2023 | Crysvita |
| Phadia US INC. | $43.16 | 2021-2024 | Immunocap |
| Smith+Nephew, INC. | $40.74 | 2022 | |
| Hologic Sales and Service, LLC | $26.60 | 2025 | Aptima, Thinprep 2000 Processor |
| Celgene Corporation | $24.61 | 2021 | |
| Verrica Pharmaceuticals INC. | $21.27 | 2024 | Ycanth |
| Seqirus USA INC | $19.50 | 2022 | |
| Sanofi Pasteur INC. | $17.86 | 2021 | |
| Genzyme Corporation | $16.05 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.62 | 2019 | |
| Vertical Pharmaceuticals, LLC | $13.49 | 2024 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.